Haag-Streit USA has appointed Alcon Laboratories Inc. as its exclusive distributor in the United States for an optical biometer (Lenstar LS900).
Ophthalmology Times Staff Reports
Aton Pharma Inc. has launched an authorized generic version of its timolol maleate ophthalmic gel-forming solution (Timoptic-XE). The non-selective beta-adrenergic receptor blocking agent is indicated in the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma. The company also will continue to make available timolol maleate under the brand name.
Bausch + Lomb has relaunched its multipurpose contact lens solution (renu fresh) in a clear bottle designed to enable users to see exactly how much solution is remaining.
Acucela Inc. and Otsuka Pharmaceutical Co. Ltd. have received fast-track designation from the FDA for ACU-4429, an investigational oral treatment for dry age-related macular degeneration.
The FDA has accepted for review the supplemental new drug application (sNDA) of ISTA Pharmaceuticals Inc. for once-daily bromfenac ophthalmic solution (XiDay).
The FDA has accepted the filing of Lux Biosciences? new drug application for oral voclosporin (Luveniq) and has granted the application priority review, according to the company.
Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.
The FDA has reopened a public docket to receive information and comments about LASIK devices, it was reported in the Nov. 13 Federal Register. The agency will accept remarks until Nov. 15, 2010.
The Centers for Medicare and Medicaid Services has stopped recognizing code Q2024 to pay for the office-based ophthalmic use of bevacizumab (Avastin, Genentech).
NeoVista Inc.'s new epimacular brachytherapy system (Vidion Anti-Neovascular Surgical System) for the treatment of age-related macular degeneration is now available in the United Kingdom